Souvenir Program - Philippine Society of Medical Oncology

Message

The COVID 19 pandemic threw all of us out of our comfort zones, forcing us to face a lot of tremendous changes.

Changes and transitions are never easy. But we are challenged to adapt, to evolve and to move forward despite the uncertainty, supporting and assisting each other along the way.

We have learned to face a lot of new things -- new ways of relating with each other – we’ve put on pause our hugs and our kisses, we’ve put on pause our weekend family gatherings, we paused on our yearly vacations, and a lot of other things that we’ve learned to love doing.

But we can’t pause on establishing connections and nurturing relationships. We don’t pause on caring for our patients, we don’t pause on serving, we don’t pause on learning.

So, let the next six days be exciting opportunities for all of us -- opportunities for the organizers to serve, opportunities for the speakers to share, and opportunities for everyone in PSMO to learn and to reconnect with each other, like how we always envision our midyear conventions to be.

Welcome everyone! Welcome to our Midyear Convention!

Mabuhay ang PSMO!

BUENAVENTURA C. RAMOS, JR, MD, FPCP, FPSMOPresident

Message

Our 18th midyear convention is a landmark in our society’s half a century of being at the forefront of medical oncology in the Philippines. For the first time, we are assembling as one society in the halls of a virtual platform.

The pandemic has almost led to this event’s cancellation, but, through the generosity of the officers and members of the PSMO, the dedicated and reliable organizing committee, and our partners—for which we are grateful—we are able to push through despite having only six weeks, instead of the usual several months, from committee formation to task execution. We have also been maximizing the use of online modalities to connect and bond our physicians across the archipelago.

As the crux of all these efforts, our theme for this year is “Heal. Pray. Live: Celebrating the Filipino Survivor.” We gather to revitalize “healing” as we examine challenges and share advancements in our specializations. The goal of our scientific discussions thus goes beyond the realm of theory. In our hope to influence policy directions and uplift the lives of our patients, the words of our father Hippocrates resound: “Wherever the art of Medicine is loved, there is also a love of Humanity.” Indeed, as we look forward to enriching the course of medical oncology, we affirm that, wherever the science of Medicine is practiced, there is also a love for Life’s Author.

We welcome you to the 18th Midyear and 1st Virtual Convention of the Philippine Society of Medical Oncology! Together, let us continue committing ourselves to the Filipino survivor.

JOSEPHINE P. CONTRERAS – TOLENTINO, MD, FPCP, FPSMOOverall Chair, 18th Midyear Convention

Message

Every year, we the members of the PSMO, look forward to our midyear convention as our “out-of-town breather”, a time for some relaxed learning, a time to visit local tourist spots of the host city and a time for team building. When the news of the lockdown came, we were all unprepared on how to deal with this crisis that has affected every aspect of our lives.

This year’s theme, “Heal.Pray.Live:Celebrating the Filipino Survivor” is very apt and providential. Indeed, survivorship has a much more profound meaning now than how we understand it as medical oncologists. Humanity has witnessed and surpassed a multitude of tragedies and injustices, such as natural disasters, war and discrimination, and now this COVID-19 pandemic. Despite this, I believe that the Filipino, cancer survivor or not, will emerge stronger and will remain resilient, unshakeable and steadfast in their faith. Even if we cannot bond physically, we can still connect virtually and spiritually as we have done during the lockdown. Let us draw inspiration from our keynote speaker, Dr. Corazon Ngelangel, a public health advocate by heart and from all our speakers as they discuss scientific updates which we can use when we go back to our practice. I pray for mental and physical strength for each one of us, as we carry on with our lives during these extraordinary times.

AGNES EVANGELISTA GOROSPE, MD, FPCP, FPSMOChair, Scientific Committee18th Midyear Convention

6:30PM - 6:50PM OPENING CEREMONIES OPENING PRAYER by Fr. Jerry Orbos, SVD WELCOME ADDRESS Agnes E. Gorospe, MD - Scientific Committee Chair

OPENING REMARKS Josephine P. Contreras-Tolentino, MD - Overall Chair

PSMO PRESIDENT’S MESSAGE AND OPENING OF THE MIDYEAR CONVENTION Buenaventura C. Ramos, Jr., MD

INTRODUCTION OF THE KEYNOTE SPEAKER Session I6:50 - 7:20PM “Celebrating the Filipino Survivor” Keynote Speaker: CORAZON A. NGELANGEL, MD 7:20 - 7:30PM Heal, Pray, Live: Video Presentation

Session II: 7:30 - 8:10PM Treating HER right: Optimizing Treatment in HER2+ Early Breast Cancer Speaker: MARIA LUISA T. ABESAMIS-TIAMBENG, MD Sponsor: Roche Philippines, Inc.

8:10 - 8:50PM More Years of Unforgettable Moments for your ALK+ Patients: Alectinib (Alecensa ®) for Advanced/ Metastatic ALK+ Non-Small Cell Lung Cancer Speaker: GERARDO H. CORNELIO, MD Sponsor: Roche Philippines, Inc.

8:50 - 9:10PM LIVE Q&A Moderator: MA. PAMELA D. PATDU, MD

9:10 - 9:15PM CLOSING

Scientific ProgrammeWEDNESDAY – JULY 1, 2020

8:00am – 5:00pm VISIT TO VIRTUAL BOOTHS

Session III: 6:30 - 7:10PM Sustaining Affordable Breast Cancer Care Through Biosimilars Speaker: CHRISTINA G. GALVEZ, MD Sponsor: Mylan Philippines

7:10 - 7:25PM TEAM “HEAL” PRESENTATION

7:25 - 8:05PM The Heritage Study and Real World Experience Speaker: MARIA LUISA T. ABESAMIS-TIAMBENG, MD Sponsor: Mylan Philippines.

8:05 - 8:20PM LIVE Q&A Moderator: JHADE LOTUS P. PENEYRA,MD



Session IV: 6:30 - 7:10PM Benefits of Ovarian Function Suppression in the Management of Pre-Menopausal Breast Cancer Speaker: JERRY Y. TAN CHUN BING, MD Sponsor: Astra Zeneca, Philippines

7:10 - 7:25PM TEAM “PRAY” PRESENTATION

7:25 - 8:05PM Evolving Strategies in the Management of EGFRm Non-Small Cell Lung Cancer Speaker: GERARDO H. CORNELIO, MD Sponsor: Astra Zeneca, Philippines

8:05 - 8:20PM LIVE Q&A Moderator: KENNETH G. SAMALA, MD


THURSDAY – JULY 2, 2020

FRIDAY – JULY 3, 2020


Session V: 6:30 - 7:10PM When Traditional Therapy is No Longer Enough Speaker: CHRISTINA G. GALVEZ, MD Sponsor: Pfizer, Inc.

7:10 - 7:25PM TEAM “LIVE” PRESENTATION

7:25 - 8:05PM Let’s Talk Palbociclib Speaker: RUBI K. LI, MD Sponsor: Pfizer, Inc.

8:05 - 8:20PM LIVE Q&A Moderator: JERRY Y. TAN CHUN BING, MD



Session VI: 6:30 - 7:00PM INDUCTION OF NEW ASSOCIATE MEMBERS Inducting Officers: CHERRY M. MARQUEZ, MD Chair, Committee on Credentials and Membership

BUENAVENTURA C. RAMOS, JR., MD PSMO President

7:00 - 8:30PM Epoetin Alfa/ESAs in the Treatment of Chemotherapy-Induced Anemia Speaker: PRISCILLA B. CAGUIOA, MD Sponsor: Bio Oncology

LIVE Q&A Moderator: DENNIS L. SACDALAN, MD

8:30 - 8:35pm END OF SCIENTIFIC SESSIONS AND CLOSING

8:35 – 9:15PM PSMO BUSINESS MEETING

SATURDAY – JULY 4, 2020

SUNDAY – JULY 5, 2020


Session VII: 6:30 - 8:00pm Benefit Outcomes in Advanced Metastatic Breast Cancer: Patient Experiences on Eribulin Therapy Speaker: CORAZON A. NGELANGEL, MD Sponsor: Hi-Eisai, Philippines

Exploring HCC Management: Targeted Therapy and its Role Amidst Conventional and Emerging Treatment Modalities Speaker: STEPHEN LAM CHAN, MBBS (HK) Sponsor: Hi-Eisai, Philippines

LIVE Q&A Moderator: ANNIELYN BERYL A. ONG-CORNEL, MD

8:00 - 9:00pm FELLOWSHIP NIGHT Team Presentation Presentation of Tiktok Videos

Awarding: Best Team Presentation Best Tiktok Challenge Best Virtual Booth Experience

GRAND RAFFLE

9:00 - 9:05PM CLOSING REMARKS BY THE PRESIDENT OF PSMO BUENAVENTURA C. RAMOS JR., MD

MONDAY – JULY 6, 2020

Curriculum VitaeFR. JERRY M. ORBOS, SVD

Fr. Jerry is a member of the Society of Divine Word (SVD) and was ordained a priest on October 25, 1980. He spent 4 years in South Korea as a missionary and became the Mission Director of SVD Philippines from 1990 to 2014. He writes a regular Sunday column “Moments” in the Philippine Daily Inquirer and has written books from his reflections and anecdotes from which the readers draw

inspiration day to day.

In July 2018, he was diagnosed with Lung Cancer and underwent the standard of care treatment. He says that he is “going public”, not for sympathy, but for God’s glory! Today, Fr. Jerry speaks of his cancer journey and survivorship to inspire many others. He shared that the, “reality of cancer opened up the reality of death, but instead of being afraid, live fully and love truly until we die.” He also motivates us not to be a slave for work, but instead think about health, family, God, and seek a meaningful life.” For us oncologists, he shares his spiritual wisdom to work for others and with others and to realize that our profession is also a mission from God. He motivates us to continue being professional but do not forget to be personal. And with bits of humor, reminding cancer patients to “focus on the humor... not the tumor.”

CORAZON A. NGELANGEL, MD, FPCP, FPSMO, MSCE, FPSO, PhD

She is a medical oncologist, prolific writer and researcher, with an MS in Clinical Epidemiology as a Rockefeller Scholar at the University of Pennsylvania and a PhD in Organization Development (SAIDI). She is the former head of the UP-Philippine General Hospital and of the Section of Medical Oncology of Jose R. Reyes Memorial Medical Center, whom

she founded based from the DOH mandate. She has also been a catalyst in the initiation of two cancer support groups, ARUGA and Kapisanan ng may K.

She is the past president of the Philippine Society of Medical Oncology (PSMO) and a member of the Advisory Council for the DOH Philippine Cancer Control Program and has been a Philippine Cancer Society, Inc. (PCSI) volunteer since 1988.

She was awarded Most Outstanding Medical Oncologist by the Philippine Society of Medical Oncology (PSMO), Most Outstanding Oncology Researcher and Teacher by the Philippine Society of Oncology (PSO) and the Philippine College of Physicians (PCP).

She has also been a consistent international publication awardee of the Univeristy of the Philippines.

MA. LUISA ABESAMIS-TIAMBENG, MD, FPCP, FPSMO

Dr. Tiambeng graduated from fellowship training in Medical Oncology at University of the Philippines - Philippine General Hospital in 2003. After a few years, she decided to further train as fellow in Medical Oncology at the National Cancer Centre in Singapore to advance her learnings in the field. Her

professional career rose to greater heights subsequently.

Dr. Tiambeng is the current Director of the Cardinal Santos Cancer Center and the Chief of the Section of Medical Oncology. She also actively practices in Rizal Medical Center as Medical Specialist III.

She has served as Principal Investigator to various clinical trials and primary author of several published local and international researches.

GERARDO H. CORNELIO, MD, FPCP, FPSMO, FPSO

Dr. Cornelio obtained his Fellowship Training in Medical Oncology in the University of the Philippines-Philippine General Hospital. He pursued further training in Clinical Fellowship at the National Cancer Center Singapore.

He held past positions as follows; Chairman of the Department of Internal Medicine of San Juan de Dios Hospital and President of the Philippine Society of Medical Oncology (PSMO).

He is an author and co-author of several clinical trials in solid tumors.

He currently holds the position of Director of the Cancer Institute of St. Luke’s Medical Center - Global City.

Curriculum Vitae

CHRISTINA G. GALVEZ, MD, FPCP, FPSMO

Dr. Galvez obtained her Fellowship in Medical Oncology at the Veterans Memorial Medical Center.

She is a past President of the Philippine Breast Cancer Society and is currently one of the board examiners of the Philippine

Specialty Board for Medical Oncology.

She has strong research experiences as principal investigator and co-investigator to numerous clinical trials in lung and breast cancers.

She currently holds the position as Head of the Committee on Research at the St. Luke’s Cancer Institute-Global City.

JERRY Y. TAN CHUN BING, MD, FPCP, FPSMO

Dr. Tan Chun Bing obtained his Fellowship Training in Medical Oncology from the University of the Philippines-Philippines General Hospital.

He is an Active Consultant at the Cebu Doctors University and has participated as invited speaker in many conferences in Medical Oncology. He is also currently the Head of the Section of Oncology of the University of Cebu Medical Center.

Curriculum Vitae

RUBI K. LI, MD, FPCP, FPSMO

Dr. Li is a Past President of the Philippine Society of Medical Oncology. At present, she is an active consultant at St. Luke’s Medical Center- Quezon City and is the Head of the Ambulatory Care Unit of St. Luke’s Cancer Institute. She is also an active member of the Training Committee of the Section of Medical Oncology.

In 2015, she was the Lead of the Human Cancer Biobank Project of St. Luke’s Medical Center, the country’s first Human Cancer Biobank. She was part of the project that bids to possibly find a cancer-treatment protocol for patients by analyzing tumor specimens at the genetic material and molecular level.

She has impressive research experience- serving as principal investigator to various clinical trials on lung, breast, gynecologic, and genitourinary cancers. She is the previous Head of the Research Committee of the Section of Medical Oncology at St. Luke’s Medical Center- Quezon City.

PRISCILLA B. CAGUIOA, MD, FPCP, FPSMO, FPSHBT

Dr. Caguioa’s beginnings in Hematology-Medical Oncology started when she underwent fellowship training in Medical Oncology at University of Santo Tomas. She later on embarked to train in Hematology at Boston University Medical Center in Massachussetts, USA.

She is Past President of the Philippine College of Physicians, Philippine Society of Hematology and Blood Transfusion, and Philippine Society of Medical Oncology. These achievements are among the highlights of her career as a Hematologist-Medical Oncologist.

An added feather to her cap, she was awarded the Most Outstanding Medical Oncologist by the Philippine Society of Medical Oncology in 2013 and the Most Outstanding Physician by the Philippine Medical Association in 2015.

Curriculum Vitae

She is now the Chief of Section of Hematology at St. Luke’s Medical Center. She previously held the position of Director of St. Luke’s Cancer Institute- Quezon City. She is also the Chief of the Section of Medical Oncology of the Department of Internal Medicine of the Faculty of Medicine and Surgery at University of Santo Tomas.

She has shared her research expertise as Principal Investigator to multiple local, regional, and international clinical trials.

CHAN LAM STEPHEN, MBBS (HK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (London)

Associate Professor

Dr. Stephen L. Chan is currently the Associate (Clinical) Professor of Department of Clinical Oncology at CUHK. Dr. Chan

graduated from The University of Hong Kong in 2000. He obtained the membership of the Royal College of Physician in United Kingdom in 2003 and fellowship of Hong Kong College of physician in Medical Oncology in 2007, respectively.

Dr. Chan’s main research area is clinical research for gastrointestinal and hepatobiliary cancers, with particular research interest in liver cancer. Dr. Chan has more than 60 publications including first-authored papers in the Lancet and Journal of Clinical Oncology. Dr. Chan has been the principal investigator of a number of clinical trials including projects funded by General Research Fund and Hong Kong Health and Research Fund of Hong Kong Government, as well as international grants such as the Sister Institution National Fund of MD Anderson Center for cancer. Based on his research achievement, Dr. Chan has also been awarded Gold Medal for dissertation and Young investigator award by the HK College of Physician in 2007 and 2008, respectively.

Curriculum Vitae

Abstract

Treating HER Right: Optimizing cure in HER2+ early breast cancer

MA. LUISA ABESAMIS-TIAMBENG, MD

Fast forward 15 years after the monumental trials that established the role of anti-HER2 treatment in HER2+ early breast cancer, the success achieved in the treatment landscape continues to give birth to numerous innovation. This is both an opportunity and a challenge, putting all trials into perspective in clinical practice especially in the neoadjuvant to adjuvant setting, even in the presence of residual invasive disease. This presentation aims to review the journey of anti-HER2 therapy in the year 2020 — how to optimize treatment options, improve patient outcomes, and deepen understanding on how to treat HER2+ early breast cancer.

More Years of Unforgettable Moments for your ALK+ Patients: Alectinib (Alecensa ®) for Advanced/ Metastatic ALK+ Non-Small Cell Lung Cancer

GERARDO H. CORNELIO, MD

ALK+ Non-Small Cell Lung Cancer (NSCLC) is an aggressive disease with a poor prognosis. 89 percent of patients present with stage 4 disease at diagnosis with a median survival from 6-20 months without an effective targeted therapy. In this presentation, we will learn about the newly Philippine FDA-approved treatment, Alectinib (Alecensa®), and its breakthrough benefits for ALK+ NSCLC patients. Alectinib (Alecensa®) is a highly selective and potent ALK tyrosine kinase inhibitor that inhibits tumor proliferation and is able to cross the blood brain barrier and remain in the CNS. Alectinib has a wealth of clinical evidence proving its efficacy and safety. The ALEX trial shows that at 1st line Alectinib (Alecensa®) has a median progression free survival 3x longer (34.8 months) versus the comparator arm and 10.9 months if used in 2nd line based on the ALUR study.

AbstractTHE HERITAGE STUDY

MA. LUISA ABESAMIS-TIAMBENG, MD

Over-expression of HER2 is implicated in the pathophysiology of around 25% of breast and 18% of gastric and gastroesophageal tumors. Trastuzumab has changed the treatment course for HER2+ tumors. In metastatic breast cancer, it has been proven to improve PFS, OS, and ORR. In early stage breast cancer, data shows that it cuts down the risk of recurrence or death by at least 50%. In metastatic gastric cancer, it has also been proven beneficial in improving PFS, OS and ORR. It is well tolerated with modest and manageable toxicity. Hence, it has become the gold standard in the treatment of HER2+ tumors.

Unfortunately, not all patients can sustain at least one year of Herceptin treatment, especially in a non-reimbursed economy like ours. Biosimilar Trasuzumab, therefore has the potential to improve access to this life-saving drug provided that it has no clinically meaningful difference with the reference product in terms of safety, purity and potency.

In this presentation, we shall discuss the Heritage study – the first landmark trial on Biosimilar Mylan Trastuzumab that paved the way for its approval by the EMA, US and Philippine FDA, after having successfully established its equivalence with EU Trastuzumab.

Benefits of Ovarian Function Suppression in the Management ofPre-Menopausal Breast Cancer

JERRY Y. TAN CHUN BING, MD

For the longest time, tamoxifen has been the standard of care treatment for premenopausal hormone positive breast cancer patients. With recent results of studies in this patient population, more options are now available including novel hormonal and targeted therapies along with ovarian function suppression. This session will discuss these options and will hopefully help improve the management of premenopausal breast cancer patients, putting in mind not only efficacy and safety, but as well as fertility preservation.

Evolving Strategies in the Management of EGFRm Non-Small Cell Lung Cancer

GERARDO H. CORNELIO, MD

EGFR-TKIs have redefined treatment in EGFRm advanced NSCLC. Several EGFR TKIs have similarities and differences in terms of efficacy, effect on CNS disease and safety

The third generation EGFR TKI, Osimertinib, demonstrated a clinically and statistically significant improvement in patient outcomes across different stages of NSCLC. Osimertinib’s FLAURA Study is the first trial that shows that an EGFR TKI for lung cancer can translate PFS into an OS benefit. Another of its study, ADAURA, is the first global trial that demonstrated that an EGFR TKI, Osimertinib, can show a statistically significant improvement in DFS in patients with stage IB/II/IIIA EGFR, NSCLC

When “One” is No Longer Enough

CHRISTINA G. GALVEZ, MD

For more than 20 years, tamoxifen and aromatase inhibitors have been the standard of care for the treatment of HR+/Her2- metastatic breast cancer. In the advent of innovative medicine however, more and more strategies are discovered to provide progressively increasing benefits especially when used in the first line setting.

The discovery of CDK 4/6 inhibitors revolutionized clinical practice through its unique mechanism of action by providing synergistic benefit when given alongside endocrine therapy as dual inhibition.

Abstract

AbstractLet’s Talk Palbociclib

Confidence in Strength:Sharing the World-wide experience of Palbociclib

RUBI K. LI, MD

Since 2015, Ibrance has transformed treatment guidelines for HR+/Her2- advanced/metastatic breast cancer by being the first drug in its class that showed improved progression free survival while maintaining acceptable quality of life. Backed up by a wide gamut of molecular research, clinical data, and real-world experience – Ibrance remains to be the leading CDK 4/6 inhibitor globally.

Role of ESAs in the Management of Chemotherapy-Induced Anemia

PRISCILLA B. CAGUIOA, MD

Cancer-related anemia is still a relevant problem that requires attention especially since it potentially worsens with chemotherapy. Fatigue is a common concern and is associated with poor quality of life. Through the development of tumor hypoxia, anemia also adversely affects prognosis and survival by inducing chemoresistance, genetic instability, evasion of apoptosis and sustained angiogenesis. Correction of anemia through blood transfusion has been shown to improve quality of life. However, the disadvantages and risks of transfusion need to be considered. Erythropoietin stimulating agents (ESA) provide an alternative and safer treatment option for chemotherapy-induced anemia. ESAs produce gradual and sustained increases in hemoglobin levels, and are quite convenient to use. With today’s additional challenge of treating patients during the COVID19 pandemic, ESAs can be used to better manage the currently limited blood supplies and to avoid unnecessary exposure to infection risks through self-administration of the drug.

Benefit Outcomes in Advanced Metastatic Breast Cancer:Patient Experiences on Eribulin Therapy

CORAZON A. NGELANGEL, MD, FPCP, FPSMO, MSCE, FPSO, PhD

Treatments with survival benefit are greatly needed for women with heavily pretreated metastatic breast cancer. Eribulin mesylate is a non-taxane microtubule dynamics inhibitor with a novel mode of action and has shown to be beneficial among patients with advanced or metastatic breast cancer. We aim to showcase more on Eribulin’s role thru patient case sharing and highlight its unique characteristic shown in the EMBRACE trial and other combination studies, along with recent real world data.

Exploring HCC Management: Targeted Therapy and its Role amidst Conventional and Emerging Treatment Modalities

STEPHEN LAM CHAN, MBBS (HK), MRCP (UK), FHKCP, FHKAM (Medicine),FRCP (Edin), FRCP (Lond)

The landscape of treatment in HCC management is constantly growing with the expansion of the conventional therapies and emergence of newer treatment options. Targeted therapy is one of the modalities used in the management of liver cancer. Lenvatinib is an oral multikinase inhibitor that is approved for monotherapy in unresectable HCC and we aim to highlight Lenvatinib and the benefit it provides by sharing scientific data and experience in practice in reference to the recent trends in IO and latest consensus statements in liver cancer management.

Abstract

The Inductees

NEW ASSOCIATE MEMBERS

1. Atutubo, Cyrielle Marie N.2. Balolong-Garcia, Joanmarie C.3. Bebero, Katrina Gaelic M.4. Bendebel, Margaret Therese B.5. Borja, Bryan Adams M.6. Catedral, Lance Isidore G.7. Cruz-Ignacio, Mary Anne B.8. Cruz-Ordinario, Mel Valerie B.9. De Veyra, Jamila Marie J.10. Hilado, Joseph Riegel G.11. King, Rich Ericson C.12. Mondragon, Karen Anjela M.13. Ong, Mary Antonette G.14. Saldaña, Janelle S.15. Ting, Frederic Ivan L.16. Velasco Jr., Rogelio N.

The InducteesThe Inductees

Atutubo, Cyrielle Marie N.

Bebero, Katrina Gaelic M.

Borja, Bryan Adams M.

Cruz-Ignacio, Mary Anne B.

Balolong-Garcia, Joanmarie C.

Bendebel, Margaret Therese B.

Catedral, Lance Isidore G.

Cruz-Ordinario, Mel Valerie B.

The Inductees

De Veyra, Jamila Marie J.

King, Rich Ericson C.

Ong, Mary Antonette G.

Ting, Frederic Ivan L.

Hilado, Joseph Riegel G.

Mondragon, Karen Anjela M.

Saldaña, Janelle S.

Velasco Jr., Rogelio N.

Organizing Committee1ST VIRTUAL AND 18TH MIDYEAR CONVENTION

JOSEPHINE P. CONTRERAS-TOLENTINO, MDOverall Chair

HIYASMIN P. ACERO-ALEJANDRO, MDOverall Co-Chair

Scientific Program Committee

Agnes S. Evangelista-Gorospe, MDChair

Janet B. Bautista, MDCo-Chair

Virtual Events Committee

Ann Meredith U. Garcia-Trinidad, MDChair

Edgar Christian S. Cuaresma, MD Raji R. Shamaileh, MD Co-Chair Co-Chair

Invitation and Publicity Committee

Nelson A. Laja, MDChair

Lou Jorel P. Tia, MD Kenny Jun N. Demegillo, MD Co-Chair Co-Chair

Publications Committee

Vanina A. Htun-Javier, MDChair

Digital Booth Committee

Andrew A. Yacat, MDChair

Registration Committee

Ana Lea V. Lava, MDChair

Andrea Monica Talag-Espinosa, MDCo-Chair

Socials Committee

Jay T. Datukan, MDChair

Cherry M. Marquez, MD Elaine Marisse H. Co-Chair Ilagan-Cargullo, MD Co-Chair

Ways and Means Committee

Julie Ann R. Tapispisan, MDChair

Maria Diana Aileen C. Bautista, MDCo-Chair

Buenaventura C. Ramos, Jr., MDPresident

Arnold John B. Uson MDVice President

Governing Council

Grace S. Nilo, MDSecretary

Governing Council

Carlos Dy, MDTreasurer

JosephineContreras-Tolentino, MD

Internal Auditor

Honey Sarita J. Abarquez, MD

Nestor L. Atienza, MD

Council Members

Abdiel P. Galicia, MD

Rosario V. Pitargue, MD

Council Members

Jose S. Garcia, Jr., MDImmediate Past President

Governing Council Sponsors

Sponsors

Sponsors

Sponsors

Sponsors

Sponsors

Sponsors

Souvenir Program - Philippine Society of Medical Oncology

Documents